Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28071819 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL399572 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL7088576 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL12952342 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL17320247 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL4938419 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL6981275 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL13282093 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| SCHEMBL3779843 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CYP2C19RAB9APOLBTDP1 | |
| Hydrochloric Acid SCHEMBL31029934 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CYP2C19RAB9APOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2008-07-10 | — | — | US | disclosed |
| US-7211601-B2 | Pharmaceutically active pyrrolidine derivatives | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-05-01 | — | — | US | disclosed |
| EP-1268419-B1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-21 | — | — | EP | disclosed |
| EP-1268418-B1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS (AN) | 2006-06-14 | — | — | EP | disclosed |
| US-7018988-B2 | Pharmaceutically active pyrrolidine derivatives as Bax inhibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-03-28 | — | — | US | disclosed |
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | MERCK SERONO SA (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212012-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, CNR1, PRLHR | ALDH1A1 3384/4885CYP2C19 1014/4885RAB9A 2840/4885 |
| US-20080167318-A1 | Pharmaceutically active pyrrolidine derivatives | OXTR, PRLHR, NR0B1 | ALDH1A1 3219/4885CYP2C19 812/4885RAB9A 2058/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | ALDH1A1 3249/4885CYP2C19 906/4885RAB9A 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.